tbuckley/cabot-search huggingface dataset:
Mcl-1 and bcl-2 expression in neuroendocrine carcinoma (NEC) and potential for new therapeutic target.
Authors: M. Batus, D. C. McFarland, J. Coon, S. Basu, M. Pool, R. Myint, K. K. Walters, M. J. Fidler, P. D. Bonomi
Journal: Journal of Clinical Oncology (2010)

e21039 Background: Minimal advances have been made in treatment of NECs including small cell lung cancer (SCLC). Molecular markers may allow us to identify patients most likely to benefit from new treatment. Our objective was to determine frequency and prognostic significance of Mcl-1 and Bcl-2 expression in these tumors and correlate this data with clinical outcomes. Mcl-1 is one of six anti-apoptotic BCL2 family proteins. Bcl-2 expression has previously inferred worse outcomes in SCLC. Methods: Tissues from 150 patients treated as SCLC were stained for multiple molecular markers including Bcl-2 and Mcl-1. Frequency and intensity of expression were measured on a scale of 0-4 (freq 0 = no expression, freq 1 = 1-10%, freq 2 = 11-35%, freq 3 = 36-70%, freq 4 = 71-100%). Tumor marker frequency and intensity were assimilated as a product of the two on a scale of 0-16. The sum of the Mcl-1 and Bcl-2 products was calculated. Charts were retrospectively reviewed for stage, performance status, dates of diagnosis/death, survival, and treatment. Results: Of the original 150 tissue samples, 129 were analyzed for Mcl-1 frequency. 56% expressed frequency of 1 or greater; however, the association with overall survival (OS) was not significant. Median OS was 154 weeks, 31 pts underwent resection of tumor. Of the 112 samples analyzed for Bcl-2 frequency, 73% expressed frequency of 1 or greater; pts with Bcl-2 frequency >3 had significantly shorter median OS (162.1 vs. 58.1 weeks) (p=0.0197). 51 samples expressed both Mcl-1 and Bcl-2 at frequency of 1 or greater. The summation of products of Mcl-1 and Bcl-2 resulted in significantly shorter OS (107 vs. 162 weeks) (p=0.00802) for patients with sum of products > 11. Conclusions: Our retrospective study revealed significantly shorter OS associated with higher frequency of Bcl-2. The sum of Mcl-1 and Bcl-2 products resulted in more significant negative relationship with OS than Bcl-2 expression alone (p=0.00802 vs. 0.0197). The combination of Bcl-2 and Mcl-1 expression may be more predictive of patients likely to have a poor outcome. These patients may benefit from therapies targeting apoptotic pathway. Frequency of marker expression on 0-4 scale Mcl-1 Bcl-2 0 43% 26% 1 20.2 7% 2 21.7 15% 3 10.9 33% 4 3.8 35% No significant financial relationships to disclose.
Tumoral predominance and oncologic treatment possibilities of older patients in Argentina.
Authors: A. P. Hunis, A. Deves, D. Schlegel, M. Hunis, P. Torrisi, G. Saidon, M. E. Leonardi, M. Risk
Journal: Journal of Clinical Oncology (2010)

e19682 Background: Age is one of the principal factors to determine the most adequate oncological treatment strategy. The increased life expectancy had an impact in the number of aged patients with cancer, thus the way these patients are treated should be revised. The aged patients group, over 65 years old, are the 16% of the total populations, but the portion of them suffering cancer are around the 60%. Objective: to describe the profile of our aged patients (over 65 years old) stratified according the clinical and therapeutic possibilities. Methods: Retrospective, descriptive and comparative study in which they have evaluated patients admitted at the Centro Oncológico Buenos Aires, during the period from January 2004 until December 2007. A total of 1457 patients were evaluated (range from 16 to 94 years old), all of them with confirmed diagnostic of cancer (histological exam) 54% (787 patients) were under 65 years of age and 46% remaining (670 patients) were between 65 to 94 years of age. Results: Tumor vs age (years mean ±standard deviation-sdt-) urologic tumors 70±6, sarcoma 69±8, lung 69±5, prostate 69±4, unknown primary 68±4, skin 70±6, hematologic 70±5, mesotelioma 66±1, melanoma 72±9, breast 69±5, gynecologic 71±8, gastroenterology 71±7, head and neck 72±8, colorectal 70±6; treatment vs age (years mean±sdt) radiotherapy 70±9, radiotherapy +hormothetrapy, 69±4, radiotherapy 70±7, chemotherapy + radiotherapy + hormotherapy,69±6, chemotherapy + radiotherapy, 69±5, chemotherapy + hormotherapy, 72±9, chemotherapy 70±6, and hormotherapy 71±3. There were not statistical differences among groups. Conclusions: Our study confirms that: the impact of cancer in patients over 65 years in our environment is similar to that observed in other so-called developed countries (USA and Europe) despite of cultural, nutritional and hygienic differences.We can make cancer treatments (surgery, radiotherapy, chemotherapy, hormotherapy and others) in this patient group. The age should not be the only parameter to decide the treatment. The comorbidities should be taken into account when deciding on a therapeutic behavior. No significant financial relationships to disclose.
Hepatic Myelopathy after Transjugular Intrahepatic Portosystemic Shunt: Prevalence, Risk Factors, and Long-Term Outcome
Authors: S. Ren, Y. Lv, Z. Wang, M. Bai, W. Zhang, J. Niu, Z. Yin, C. He, W. Guo, B. Zhang, X. Meng, J. Cai, G. Han
Journal: Journal of Hepatology (2016)
RORgt Inhibition in the Liver Prevents Hepatic Fibrosis Progression, a Proof of Concept Study with a Potent, First in Class, Hepatocentric RORgt Inverse Agonist
Authors: Z. Majd, J.-F. Delhomel, P. Delataille, I. Delbaere, M. Le Parquier, D.W. Hum, B. Staels, R. Walczak
Journal: Journal of Hepatology (2016)
Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells
Authors: Barila' Gregorio, Antonella Teramo, Giulia Calabretto, Chiara Ercolin, Albana Lico, Antonio Branca, Tamara Berno, Anna Cabrelle, Elisa Boscaro, Monica Facco, Livio Trentin, Francesco Piazza, Gianpietro Semenzato, Renato Zambello
Journal: Blood (2015)
Nutritional, Metabolic and Immunological Effects of Intravenous Lipid Emulsions in Patients with Advanced Alcohol Related Liver Disease
Authors: L. Anand, Y.K. Joshi, J. Benjamin, P. David, A. Kumar, V. Pandit, N. Trehanpati, V. Bhatia, S.K. Sarin
Journal: Journal of Hepatology (2016)
Evaluation of Effects of Concomitant Medications for Non-Alcoholic Steatohepatitis and Associated Comorbidities on Histological Improvements with Obeticholic Acid
Authors: K.V. Kowdley, M.F. Abdelmalek, A.J. McCullough, R. Loomba, B. Hameed, N.P. Chalasani, B.A. Neuschwander-Tetri, S. Hazra, J. Chen, R. Shringarpure, D. Shapiro, A.J. Sanyal
Journal: Journal of Hepatology (2016)
P1.31: Pleural Empyema and Broncho Pleural Fistula After Lung Resection: Analyses of 29 Patients Treated in our Clinic
Authors: Fadil Gradica, Lutfi Lisha, Dhimitraq Argjri, Cani Alma, Fahri Kokici, Flora Gradica, Valbona Rexha, Sali Gradica, Donika Ahmati, Perlat Kapisyzi
Journal: Journal of Thoracic Oncology (2016)
Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
Authors: J. D. Patel, T. A. Hensing, F. Rademaker, E. Hart, C. K. Obasaju, J. Treat, D. Milton, P. D. Bonomi
Journal: Journal of Clinical Oncology (2008)

8044 Background: Pemetrexed in combination with carboplatin has been shown to have promising activity, particularily in adenocarcinoma and large cell carcinoma, as well as superior toxicity profile in advanced NSCLC. Bevacizumab has been shown to improve survival of patients with advanced NSCLC when combined with other platin doublets. This study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab was designed to evaluate toxicities and estimate median time to progression of this novel regimen. Methods: Pts must be chemotherapy naive, stage IIIB (effusion) or IV non-squamous NSCLC, PS 0–1, and have no evidence of CNS metastases. Patients receive pemetrexed 500 mg/m2, carboplatin AUC 6, and bevacizumab 15 mg/kg. Treatment is repeated every 21 days for 6 cycles. For patients with SD or PR, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg are continued every 21 days until disease progression or toxicity. All patients receive folic acid, vitamin B12 and steroid prophylaxis. Results: From 8/05 - 7/07, 51 patients were enrolled: 45% male, median age 63 (range 34–80.5). One patient enrolled and subsequently refused treatment. Median follow up is 9.5 months. Median # of cycles was 6 (range 1 to 32). 30 patients (60%) completed ≥ 6 cycles of therapy, and 7 (14%) have completed ≥ 18 cycles of therapy. Grade 3/4 toxicities included: anemia (6%/0), thrombocytopenia (0/6%), leucopenia (4%/0); non-hematologic toxicities included: proteinuria (2%/0),venous thrombosis (4%/2%), arterial thrombosis (2%/0), fatigue (8%/0), and diverticulitis (6%/2%). There were no > grade 3 hemorrhagic events nor did any patients experience grade 3/4 hypertension. 49 patients were evaluable for response 1 CR and 23 PRs were observed for ORR of 49% (95% CI, 35 to 61%). 31 of 49 patients have experienced progression with a median time to progression of 7.2 months. 25 of 50 patients have died with a median survival of 14.0 months. Conclusions: Treatment with pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab in pts with advanced non-squamous NSCLC is feasible with an acceptable toxicity profile. The encouraging activity justifies further development of this regimen. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Lilly Oncology Lilly Oncology Genentech™ BioOncology, Lilly Oncology Genentech™ BioOncology, Lilly Oncology
Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).
Authors: Olivier Dubreuil, Jean Baptiste Bachet, Pascal Hammel, Jerome Desrame, Aurelia Meurisse, Thierry Andre, Philippe Debourdeau, Jérôme Dauba, Thierry Lecomte, Jean Francois Seitz, Christophe Tournigand, Thomas Aparicio, Véronique Guerin Meyer, Julien Taïeb, Sandrine Hiret, Julien Volet, Amandine Monier, Benoist Chibaudel, Franck Bonnetain, Christophe Louvet
Journal: Journal of Clinical Oncology (2017)

350 Background: Nab-paclitaxel plus gemcitabine regimen (NABGEM) became a standard in first-line patients (pts) with metastatic pancreatic adenocarcinoma (mPAC). The AFUGEM trial evaluated the efficacy and safety of nab-paclitaxel plus simplified LV5FU2 (NABFU). Methods: Main eligibility criteria were: untreated mPAC, ECOG PS≤2. Pts received nab-paclitaxel (125 mg/m 2 on d1, 8 and 15) plus gemcitabine (1000 mg/m 2 on d1, 8 and 15) or plus simplified LV5FU2 (leucovorin 400 mg/m 2 , 5FU bolus 400 mg/m 2 followed by 2400 mg/m 2 given as a 46-hour continuous infusion on d1 and 15), one cycle every 4 weeks in both arms, ratio 1:2, respectively. The primary end point was observed progression-free survival (PFS) rate at 4 months (m). A Fleming 2-stage design was used with a targeted (H1) 4m-PFS rate of 50% in NABFU arm and an uninteresting 35% rate (H0, unilateral alpha of 5% and power of 80%). Results: 114 pts were included: NABGEM n=39, NABFU n=75. Baseline characteristics were well balanced: median age 66 years (45-86), ≥2 metastatic sites 36.8%, ECOG PS 0-1 84.2% and 2 15.8%, at the exception of pain more frequent in the NABFU arm (38.5% vs 56.0%). In mITT population, the observed 4m-PFS rates were of 55.4% [95% CI, 45-63] in NABFU Vs 53.9% [95% CI, 39.6-67.7] in NABGEM. Disease control rates were 65% (95% CI, 53-76) and 62% (95% CI, 45-77) respectively. After a follow-up of 24.3m, median PFS were 5.9 [95% CI, 3.6-7.4] v 4.9 months [95% CI, 2.1-7.7] [HR=0.79, 95% CI: 0.52-1.20]. Grade 3-4 adverse events were more frequent in NABGEM (77% v 87%). At tumor progression, in the NABFU arm, 50 patients (66%) and then 13 patients (17%) received a second and third line of chemotherapy respectively, versus 22 patients (56%) and 6 patients (15%) in the NABGEM arm. Median OS were 11.4 [95% CI, 8.8-16.5] v 9.2 months [95% CI, 6.0-13.6] [HR=0.61, 95% CI: 0.40-0.95], respectively. The 12 and 18-months OS rates in NABFU vs NABGEM arm were 48% Vs 41% and 34% Vs 13%, respectively. Conclusions: Nab-paclitaxel plus simplified LV5FU2 appears at least as active as gemcitabine plus nab-paclitaxel in mPAC. The toxicity profile is safe and tolerable. This regimen deserves evaluation in a phase III trial. Clinical trial information: NCT01964534.
Phase Angle as an Early Nutritional Marker of Short-Term Outcome in Hospitalized Patients with Cirrhosis
Authors: A. Ruiz-Margáin, R. Macias-Rodriguez, L. Chi-Cervera, S. Rios-Torres, P. Rodriguez-Cordova, G. Osalde-Solís, O. Mendez-Guerrero, F.J. Cubero, A. Torre
Journal: Journal of Hepatology (2016)
Increased Membrane Proteinase 3 Expression on Neutrophils in Patients with Infectious Disease.
Authors: Takeshi Matsumoto, Toshihiro Kaneko, Hideo Wada, Yuko Kamikura, Toshihiko Kobayashi, Tsutomu Nobori, Hiroshi Shiku, Deborah J. Stearns-Kurosawa, Shinichiro Kurosawa
Journal: Blood (2004)
Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,
Authors: Meletios Athanasios Dimopoulos, Antonio Palumbo, Roman Hajek, Martin Kropff, Maria Teresa Petrucci, Philip Lewis, Stefanie Millar, Jingshan Zhang, Jay Mei, Michel Delforge
Journal: Blood (2011)
Chronic Hepatitis B is Associated with Increased Cardiovascular Risk Assessed by Intima-Media Thickness
Authors: M. Riveiro-Barciela, F. Martinez-Valle, I. Sanz-Perez, C. Marcos-Fosch, D. Tabernero, M. Homs, F. Rodríguez-Frías, R. Esteban, M. Buti
Journal: Journal of Hepatology (2016)
Governance and Standards in International Clinical Research: The Role of Transnational Consortia
Authors: Raffaella Ravinetto, Sören L. Becker, Moussa Sacko, Sayda El-Safi, Yodi Mahendradhata, Pascal Lutumba, Suman Rijal, Kruy Lim, Shyam Sundar, Eliézer K. N'Goran, Kristien Verdonck, Jürg Utzinger, François Chappuis, Marleen Boelaert
Journal: The American Journal of Bioethics (2016)
Safety and Effectiveness of Sorafenib forthe Treatment of Hepatocellular Carcinoma in Patients with Diabetes
Authors: G. Giuseppe Di Costanzo, R. Tortora, F. Morisco, L. Addario, F. Lampasi, A.G. Lanza, M. Guarino, G. Cordone, L. Falco, N. Caporaso
Journal: Journal of Hepatology (2016)
NVR 3-778, a First-in-Class HBV Core Inhibitor, Alone and in Combination with Peg-Interferon (PegIFN), in Treatment-Naive HBeAg-Positive Patients: Early Reductions in HBV DNA and HBeAg
Authors: M.-F. Yuen, D.J. Kim, F. Weilert, H.L.-Y. Chan, J.P. Lalezari, S.G. Hwang, T. Nguyen, S. Liaw, N. Brown, K. Klumpp, O. Flores, G. Hartman, E. Gane
Journal: Journal of Hepatology (2016)
Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
Authors: Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni R.A. Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan J. Ramus, Fei Huang, Nolan Priedigkeit, Estefania Rodriguez, Michael Donovan, Faisal Khan, Tamara Kalir, Robert Sebra, Andrew Uzilov, Rong Chen, Rileen Sinha, Richard Halpert, Jean-Noel Billaud, Sharon Shacham, Dilara McCauley, Yosef Landesman, Tami Rashal, Michael Kauffman, Mansoor R. Mirza, Morten Mau-Sørensen, Peter Dottino, John A. Martignetti
Journal: Clinical Cancer Research (2016)

Purpose: The high fatality-to-case ratio of ovarian cancer is directly related to platinum resistance. Exportin-1 (XPO1) is a nuclear exporter that mediates nuclear export of multiple tumor suppressors. We investigated possible clinicopathologic correlations of XPO1 expression levels and evaluated the efficacy of XPO1 inhibition as a therapeutic strategy in platinum-sensitive and -resistant ovarian cancer.Experimental Design: XPO1 expression levels were analyzed to define clinicopathologic correlates using both TCGA/GEO datasets and tissue microarrays (TMA). The effect of XPO1 inhibition, using the small-molecule inhibitors KPT-185 and KPT-330 (selinexor) alone or in combination with a platinum agent on cell viability, apoptosis, and the transcriptome was tested in immortalized and patient-derived ovarian cancer cell lines (PDCL) and platinum-resistant mice (PDX). Seven patients with late-stage, recurrent, and heavily pretreated ovarian cancer were treated with an oral XPO1 inhibitor.Results: XPO1 RNA overexpression and protein nuclear localization were correlated with decreased survival and platinum resistance in ovarian cancer. Targeted XPO1 inhibition decreased cell viability and synergistically restored platinum sensitivity in both immortalized ovarian cancer cells and PDCL. The XPO1 inhibitor-mediated apoptosis occurred through both p53-dependent and p53-independent signaling pathways. Selinexor treatment, alone and in combination with platinum, markedly decreased tumor growth and prolonged survival in platinum-resistant PDX and mice. In selinexor-treated patients, tumor growth was halted in 3 of 5 patients, including one with a partial response, and was safely tolerated by all.Conclusions: Taken together, these results provide evidence that XPO1 inhibition represents a new therapeutic strategy for overcoming platinum resistance in women with ovarian cancer. Clin Cancer Res; 23(6); 1552-63. ©2016 AACR.
SINGLE-CENTRE 20-YEAR EXPERIENCE WITH SURGICAL TREATMENT OF THYMIC TUMOURS
Authors: Sofie Viskens, Hans Van Veer, Thomas Tousseyn, Willy Coosemans, Herbert Decaluwe, Philippe Nafteux, Paul De Leyn, Patrick Schöffski, Dirk De Ruysscher, Dirk Van Raemdonck
Journal: Journal of Thoracic Oncology (2014)
GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), is active in gastrointestinal stromal tumor (GIST) xenograft and in combination with imatinib induces long-lasting response after treatment discontinuation
Authors: Guiseppe Floris, Raf Sciot, Agnieszka Wozniak, C Deroose, P Vermaelen, Barbara Dewaele, Maria Debiec-Rychter, Patrick Schöffski
Journal: Journal of Clinical Oncology (2010)
Longitudinal analysis of physiologic MRI parameters in patients with newly diagnosed glioblastoma multiforme to predict outcome.
Authors: Y. LI, J. M. Lupo, M. C. Polley, J. C. Crane, W. Bian, S. Cha, S. M. Chang, S. J. Nelson
Journal: Journal of Clinical Oncology (2010)

2078 Background: The survival for patients with Glioblastoma Multiforme (GBM) remains heterogeneous. The reason for this is not well understood. The objective of this study is to test the predictive values of serial MRI data in relation to overall survival (OS) and progression free survival (PFS) in patients with newly diagnosed GBM. Methods: Sixty-four patients with newly-diagnosed GBM underwent conventional magnetic resonance imaging (MRI), diffusion-weighted and perfusion-weighted imaging (DWI, PWI) after surgery but prior to radiation/chemotherapy (pre-RT), immediately after RT (post-RT), and every 1-2 months thereafter until tumor progression (up to a maximum of 1 year). Chemotherapy was given concurrently; the majority of patients (81%) received temozolomide. The MRI parameters consisted of lesion volumes (contrast enhancement, T2 abnormality), normalized ADC (nADC), normalized rCBV (nCBV) and normalized recirculation factor (nRF). Kaplan-Meier survival curve was used to estimate OS and PFS. Both time-independent and time-dependent (for serial imaging data) Cox proportional hazards (PH) models were applied to evaluate the prognostic values of the imaging parameters. Results: The median OS was 84 weeks and the median PFS was 27 weeks. Increased post-RT contrast enhancing lesion volume, pre-RT and post-RT T2 lesion volumes were all associated with worse survival. The time-dependent Cox PH models showed that increased anatomic volumes and lower ADC values in contrast enhancing lesions were significantly associated with shorter OS. Higher nCBV in the T2 lesion at pre-RT and post-RT were associated with shorter PFS; the same trend was found in the time-dependent analysis. Patients with lower nRF values at pre-RT or a larger increase in nRF from pre-RT to post-RT had significantly longer PFS. Conclusions: Our studies have highlighted serial MR parameters that provide information for predicting outcome in patients with GBM. This may be valuable in making decisions concerning patient management and in better understanding the mechanisms associated with treatment effects. No significant financial relationships to disclose.
World leaders pledge action on antimicrobial resistance
Authors: Anne Gulland
Journal: BMJ (2016)

World leaders have pledged to tackle the problem of antimicrobial resistance in a declaration signed at the United Nations General Assembly in New York.

This is only the fourth time that world leaders have discussed a health matter at the assembly—having held special sessions on HIV, non-communicable diseases, and Ebola in the past—and it was described by Margaret Chan, director general of the World Health Organization, before the meeting as a “historic occasion.”

“We are here together with many partners but more importantly all the countries in the world to look at this important issue. Antimicrobial resistance is a slow motion tsunami for development, especially the health sector,” she said.

The declaration said that …
Inclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients With Diabetes
Authors: Rene Rodriguez-Gutierrez, Naykky Singh Ospina, Rozalina G. McCoy, Kasia J. Lipska, Nilay D. Shah, Victor M. Montori
Journal: JAMA Internal Medicine (2016)

Inclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients With DiabetesHealth care organizations use publicly reported performance measures for quality measurement and improvement and payfor-performance initiatives. 1 These measures should ideally promote high-quality care that is evidence based and congruent with clinical practice guidelines.However, they should also reward patient-centered care that yields optimal outcomes with the lowest risk of harm. 2 For patients with both type 1 and type 2 diabetes, high-quality care should therefore minimize the risk of hypoglycemia. 2The degree to which existing performance measures are aligned with guidelines, particularly in regard to hypoglycemia avoidance, is uncertain.We therefore conducted an environmental scan to assess the inclusion and prioritization of hypoglycemia in contemporary clinical guidelines and performance measures for patients with diabetes.
Clinical Outcome in Hospitalized Cirrhotic Patients with Bacterial Infections Treated with Empirical or Antibiogram-Guided Therapy
Authors: G. Caccamo, S. Maimone, R. Filomia, M.S. Franze, S. Tomeo, R. Spinella, T. Lembo, A. Alibrandi, P. Mondello, C. Saitta, I. Cacciola, G. Squadrito, G. Raimondo
Journal: Journal of Hepatology (2016)
Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study
Authors: P. Marcellin, Q. Xie, S.W. Paik, R. Flisiak, T. Piratvisuth, J. Petersen, T. Asselah, M. Cornberg, D. Ouzan, G.R. Foster, G.V. Papatheodoridis, D. Messinger, L. Regep, G. Bakalos, U. Alshuth, H. Wedemeyer
Journal: Journal of Hepatology (2016)
Detection of Familial Pseudohyperkalemia Among Italian Blood Donors By Genetic Screening for the R276W Mutation in ABCB6
Authors: Immacolata Andolfo, Roberta Russo, Francesco Manna, Marica Lisa Salve, Alok K. Sharma, Seth L. Alper, Lucia De Franceschi, Achille Iolascon
Journal: Blood (2015)